Source: http://www.google.com/patents/US4822776?dq=5,241,671
Timestamp: 2016-05-02 11:03:37
Document Index: 331003947

Matched Legal Cases: ['art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 2', 'art 2', 'art 1']

Patent US4822776 - Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsA mediator substance exhibiting inhibitory effect upon anabolic enzyme activity in mammals, is prepared by a method comprising gathering a sample of macrophage cells from a mammal, incubating a portion of the macrophage cells with a stimulating mate This invention was made in the course of a grant from...http://www.google.com/patents/US4822776?utm_source=gb-gplus-sharePatent US4822776 - Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)Advanced Patent SearchPublication numberUS4822776 APublication typeGrantApplication numberUS 06/792,372Publication dateApr 18, 1989Filing dateOct 29, 1985Priority dateSep 8, 1981Fee statusLapsedPublication number06792372, 792372, US 4822776 A, US 4822776A, US-A-4822776, US4822776 A, US4822776AInventorsAnthony Cerami, Masanobu KawakamiOriginal AssigneeThe Rockefeller UniversityExport CitationBiBTeX, EndNote, RefManPatent Citations (2), Non-Patent Citations (157), Referenced by (139), Classifications (45), Legal Events (5) External Links: USPTO, USPTO Assignment, EspacenetLipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
The instant application is a division of Ser. No. 414,098, filed Sept. 7, 1982, which is in turn continuation-in-part of Ser. No. 351,290, now abandoned, filed Feb. 22, 1982, by the same applicants, which in turn is a continuation-in-part of Ser. No. 299,932, now abandoned, filed Sept. 8, 1981. Applicants claim the benefit of these applications under 35 U.S.C. �120.
FIG. 1A shows the effect of serum from endotoxin-sensitive mice treated with endotoxin on adipose tissue LPL activity in endotoxin-sensitive mice. Mediator activity was observed and conclusions drawn as set forth in Example 1, paragraph E herein. The data are expressed as the mean (�SEM) of six animals for each group.
Under these conditions of culture, the cells maintain a continuous logarithmic growth at a constant rate (Chang,). C. S. et al supra.) The total number of cells that would have formed from the original untreated control culture was 82�106 cells/ml after 96 hours of incubation (FIG. 14). The addition of the macrophage mediator significantly inhibited (˜70%) cell growth. The addition of Me2 SO to the cultures yielded 42�106 cells/ml. This decrease probably reflects the growth cessation which is associated with terminal erythroid differentiation of these cells. (Chang, C. S. supra.; Lo, S.C., Aft., R. and Mueller, G. C., Cancer Res. 41: 864-870 (1981)). Combined addition of Me2 SO and the macrophage mediator produced the most profound growth inhibition (˜90%) of these cells. Heme content in cells treated with the mediator alone was not appreciably affected while the combined treatment with the mediator and Me2 SO brought about ˜40% inhibition of heme formation.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4309418 *Mar 25, 1980Jan 5, 1982Sloan-Kettering Research Institute For CancerAnti-tumor agent from human serum and processUS4684623 *Nov 26, 1985Aug 4, 1987The Board Of Trustees Of The Cetus CorporationUse of tumor necrosis factor as a weight regulator* Cited by examinerNon-Patent CitationsReference1 *Atkins, P. C. et al., J. Allergy Clin. Immunol. (JACIB), 64 (4) pp. 251 258 (1979).2Atkins, P. C. et al., J. Allergy Clin. Immunol. (JACIB), 64 (4) pp. 251-258 (1979).3 *B. Beutler et al., Journal of Experimental Medicine, at vol. 161, pp. 984 995 (May, 1985, The Rockefeller University Press).4B. Beutler et al., Journal of Experimental Medicine, at vol. 161, pp. 984-995 (May, 1985, The Rockefeller University Press).5 *Bagby, G. J. et al., Am. J. Physiol., 238, pp. 325 330, (1980).6Bagby, G. J. et al., Am. J. Physiol., 238, pp. 325-330, (1980).7 *Barclay, M. et al., Prog. Biochem. Pharmacol. 10, 76 111, (1975).8Barclay, M. et al., Prog. Biochem. Pharmacol. 10, 76-111, (1975).9 *Barney, C. C. et al., Lipton, J. M. (Ed.). Fever: International Symposium, Dallas, Tex., U.S.A., Apr. 11 12, 1979, XII 263P, Raven Press: New York, Illus. ISBN 0 89004 451 1 (08877), 0 (0), pp. 111 122 (1980).10Barney, C. C. et al., Lipton, J. M. (Ed.). Fever: International Symposium, Dallas, Tex., U.S.A., Apr. 11-12, 1979, XII+263P, Raven Press: New York, Illus. ISBN 0-89004-451-1 (08877), 0 (0), pp. 111-122 (1980).11 *Beisel, W. R., Ann. Rev. Med., 26:9 20 (1975).12Beisel, W. R., Ann. Rev. Med., 26:9-20 (1975).13 *Bornstein, D. L. et al., 38th. Annual National Meeting of the American Federation for Clinical Research, San Francisco, Calif., U.S.A., Apr. 25 1981, Clin. Res. (CLREA), 29 (2) p. 381A (1981).14Bornstein, D. L. et al., 38th. Annual National Meeting of the American Federation for Clinical Research, San Francisco, Calif., U.S.A., Apr. 25-1981, Clin. Res. (CLREA), 29 (2) p. 381A (1981).15 *Brenneman, D. E. et al., Eur. J. Cancer 11, 225 230, (1975).16Brenneman, D. E. et al., Eur. J. Cancer 11, 225-230, (1975).17 *Cameron, D. J. et al., J. Clin. Invest. (JCINA), 63 (5), pp. 972 984 (1979).18Cameron, D. J. et al., J. Clin. Invest. (JCINA), 63 (5), pp. 972-984 (1979).19 *Carey, F. J. et al., J. Clin. Invest. 37:441 (1958).20 *Carr, B. R. et al., J. Clin. Endocrinol. Metab. (JCEMA), 52 (6) pp. 1124 1128 (1981).21Carr, B. R. et al., J. Clin. Endocrinol. Metab. (JCEMA), 52 (6) pp. 1124-1128 (1981).22 *Chang, T Y, et al., J. Biol. Chem. (JBCHA) 256 (12) pp. 6174 6180 (1981).23Chang, T-Y, et al., J. Biol. Chem. (JBCHA) 256 (12) pp. 6174-6180 (1981).24 *Charles A. Dinarello, Reviews of Infectious Diseases, at vol. 6, No. 1, (Jan. Feb., 1984).25Charles A. Dinarello, Reviews of Infectious Diseases, at vol. 6, No. 1, (Jan.-Feb., 1984).26 *Chaudry, I. H. et al., Arch. Surg. 109, 412 415 (1978).27Chaudry, I. H. et al., Arch. Surg. 109, 412-415 (1978).28 *Cohen, S., Am. J. Pathol. (AJPAA), 88 (3) pp. 502 528 (1977).29Cohen, S., Am. J. Pathol. (AJPAA), 88 (3) pp. 502-528 (1977).30 *Coleman, R. A. et al., J. Biol. Chem. 253, 7256 7261, (1978).31Coleman, R. A. et al., J. Biol. Chem. 253, 7256-7261, (1978).32 *Dinarello, C. A., Fed. Proc. 38:52 56 (1979).33Dinarello, C. A., Fed. Proc. 38:52-56 (1979).34 *Eckel, R. H. et al., Biochem. Biophys. Res. Commun. 78, 288 293, (1977).35Eckel, R. H. et al., Biochem. Biophys. Res. Commun. 78, 288-293, (1977).36 *Eckel, R. H. et al., Biochem. Biophys. Res. Commun. 84, 1069 1075, (1978).37Eckel, R. H. et al., Biochem. Biophys. Res. Commun. 84, 1069-1075, (1978).38 *Edelson, P. J. et al., J. Exp. Med. 142, 1150 1164 (1975).39Edelson, P. J. et al., J. Exp. Med. 142, 1150-1164 (1975).40 *Farshtchi, D. et al., J. Bacteriol. 95:1615 (1968).41 *Fielding, C. J. et al., Arch. Pathol. Lab. Med. 101:225 (1977).42 *Fischer, C. L. et al., II: Serum Protein Abnormalities: Diagnostic and Clinical Aspects, eds. Ritzman, S. E. & Daniels, J. C. (Little Brown, Boston), pp. 331 350, (1975).43Fischer, C. L. et al., II: Serum Protein Abnormalities: Diagnostic and Clinical Aspects, eds. Ritzman, S. E. & Daniels, J. C. (Little Brown, Boston), pp. 331-350, (1975).44 *Frayn, K. N., Europ. J. Clin. Invest. 5:331 337 (1975).45Frayn, K. N., Europ. J. Clin. Invest. 5:331-337 (1975).46 *Gallin, E. K. et al., Cell Immunol. (CLIMB) 27 (2) at 348 (1976).47 *Gallin, J. I. et al., N. Engl. J. Med. 281:1081 (1969).48 *Green, H. et al., Cell 1, 113 116, (1974).49Green, H. et al., Cell 1, 113-116, (1974).50 *Green, H. et al., Cell 5, 19 27, (1975).51Green, H. et al., Cell 5, 19-27, (1975).52 *Green, H. et al., Cell 7, 105 113, (1976).53Green, H. et al., Cell 7, 105-113, (1976).54 *Grossberg, S. E. et al., Nature (London) 208:954 (1965).55 *Havel, R. J. et al., J. Clin. Invest. 39:1777 (1960).56 *Herring, W. B. et al., J. Clin. Invest. 42:79 (1963).57 *Hirsh, R. L., McKay, D. G., Travers, R. I., and Skraly, R. K., J. Lipid. Res., 5:563 568 (1964).58Hirsh, R. L., McKay, D. G., Travers, R. I., and Skraly, R. K., J. Lipid. Res., 5:563-568 (1964).59 *Hoffman Goetz, J. et al., Am. J. Clin. Nutr. (AJCNA), 32 (7) pp. 1423 1427 (1979).60Hoffman-Goetz, J. et al., Am. J. Clin. Nutr. (AJCNA), 32 (7) pp. 1423-1427 (1979).61 *Itkin, I. H. et al., J. Allergy (JOALA), 41 (2) pp. 88 89 (1968).62Itkin, I. H. et al., J. Allergy (JOALA), 41 (2) pp. 88-89 (1968).63 *Johnson, H. M. et al., Cell Immunol. (CLIMB), 44 (1) pp. 125 130 (1979).64Johnson, H. M. et al., Cell Immunol. (CLIMB), 44 (1) pp. 125-130 (1979).65 *Johnson, H. M. et al., IRCS (Int. Res. Commun. Syst.) Med. Sci Libr. Compend. (IRLCA), 4 (5) p. 187 (1976).66Johnson, H. M. et al., IRCS (Int. Res. Commun. Syst.) Med. Sci-Libr. Compend. (IRLCA), 4 (5) p. 187 (1976).67 *Juniper, E. F. et al., Clin. Allergy (CLAGB), 11 (1) pp. 61 66 (1981).68Juniper, E. F. et al., Clin. Allergy (CLAGB), 11 (1) pp. 61-66 (1981).69 *Kaliner, M., Am. Rev. Respir. Dis (ARDSB), 118 (6 Part 1), Received 1979) pp. 1015 1022 (1978).70Kaliner, M., Am. Rev. Respir. Dis (ARDSB), 118 (6 Part 1), Received 1979) pp. 1015-1022 (1978).71 *Kampschmidt, R. F. et al., J. Lab. Clin. Med. 95:616 623 (1980).72Kampschmidt, R. F. et al., J. Lab. Clin. Med. 95:616-623 (1980).73 *Kampschmidt, R. F. et al., J. Reticuloendothel. Soc. (RESJA) 28 (2) pp. 191 201 (1980).74Kampschmidt, R. F. et al., J. Reticuloendothel. Soc. (RESJA) 28 (2) pp. 191-201 (1980).75 *Kampschmidt, R. F., Ann. Okla., Acad. Sci (AOASA), 4 pp. 62 67 (1974).76Kampschmidt, R. F., Ann. Okla., Acad. Sci (AOASA), 4 pp. 62-67 (1974).77 *Kampschmidt, R. F., Lipton, J. M. (Ed.), Fever: International Symposium, Dallas, Tex., U.S.A., Apr. 11 12, 1979, XII 263P, Raven Press: New York, U.S.A., Illus. ISBN 0 89004 451 1 (08877) 0 (0), pp. 49 56 (1980).78Kampschmidt, R. F., Lipton, J. M. (Ed.), Fever: International Symposium, Dallas, Tex., U.S.A., Apr. 11-12, 1979, XII+263P, Raven Press: New York, U.S.A., Illus. ISBN 0-89004-451-1 (08877) 0 (0), pp. 49-56 (1980).79 *Kampschmidt. R. F., J. Reticuloendothel. Soc., 23:287 297 (1978).80Kampschmidt. R. F., J. Reticuloendothel. Soc., 23:287-297 (1978).81 *Kawakami, M. et al., J. Exp. Med. 154, 631 639, (1981).82Kawakami, M. et al., J. Exp. Med. 154, 631-639, (1981).83 *Keenan, R. A. et al., 65th Annual Meeting of the Federation of American Societies for Experimental Biology, Atlanta, Ga., U.S.A., Apr. 12 17, 1981, Fed. Proc. (FEPRA), 40 (3 Part 1), p. 439 (1981).84Keenan, R. A. et al., 65th Annual Meeting of the Federation of American Societies for Experimental Biology, Atlanta, Ga., U.S.A., Apr. 12-17, 1981, Fed. Proc. (FEPRA), 40 (3 Part 1), p. 439 (1981).85 *Kempf, K. E. et al., J. Immunol. (JOIMA), 119 (2) pp. 517 523 (1977).86Kempf, K. E. et al., J. Immunol. (JOIMA), 119 (2) pp. 517-523 (1977).87 *Kennerly, D. A. et al., J. Immunol. (JOIMA), 122 (1), pp. 152 159 (1979).88Kennerly, D. A. et al., J. Immunol. (JOIMA), 122 (1), pp. 152-159 (1979).89 *Korn, E. D., J. Biol. Chem. 215, 1 14 (1955).90Korn, E. D., J. Biol. Chem. 215, 1-14 (1955).91 *Korn, E. D., J. Biol. Chem. 215, 15 26 (1955).92Korn, E. D., J. Biol. Chem. 215, 15-26 (1955).93 *Krejci, J. et al., Folia. Microbiol. (FOMIA) 13 (6) p. 562.94 *Mackall, J. C. et al., J. Biol. Chem. 251, 6462 6464, (1976).95Mackall, J. C. et al., J. Biol. Chem. 251, 6462-6464, (1976).96 *Mapes, C. A., et al., Fed. Proc. (FEPRA) 36 (3) p. 1138 (1977).97 *McAdam, K. P. W. J. et al., Lancet II:572 (1975).98 *Merriman, C. R., et al., Proc. Soc. Exp. Biol. Med. (PSEBA), 154 (2) pp. 224 227 (1977).99Merriman, C. R., et al., Proc. Soc. Exp. Biol. Med. (PSEBA), 154 (2) pp. 224-227 (1977).100 *Michalek, S. M. et al., Fed. Proc. (FEPRA), 38 (3 Part 1) 1284) (1979).101 *Newborg, M. F., et al., Infec. Immun. (INFIB), 24 (3) pp. 667 672 (1979).102Newborg, M. F., et al., Infec. Immun. (INFIB), 24 (3) pp. 667-672 (1979).103 *Nilsson Ehle, P. et al., J. Lipid Res. 17, 536 541, (1976).104Nilsson-Ehle, P. et al., J. Lipid Res. 17, 536-541, (1976).105 *Okpako, D. T., Int. Arch. Allergy Appl. Immunol. (IAAAA) 40 (4 5) pp. 620 630 (1971).106Okpako, D. T., Int. Arch. Allergy Appl. Immunol. (IAAAA) 40 (4-5) pp. 620-630 (1971).107 *Olivecroma, T. et al., Fed. Proc. Fed. Am. Soc. Exp. Biol. 36, 60 65.108Olivecroma, T. et al., Fed. Proc. Fed. Am. Soc. Exp. Biol. 36, 60-65.109 *Paterson, N.A.M., et al., Fed. Proc. (FEPRA), 35 (3) p. 865 (1976).110 *Paterson, N.A.M., et al., Pneumonologie (PNMGA), 153 (2) p. 148 (1976).111 *Peterson, C. M. et al., Diabetes, 26:507 509 (1977).112Peterson, C. M. et al., Diabetes, 26:507-509 (1977).113 *Plescia, O. J. Cell Immunol. (CLIMB) 27 (2) at 348 349 (Received 1977) (1976).114Plescia, O. J. Cell Immunol. (CLIMB) 27 (2) at 348-349 (Received 1977) (1976).115 *Pyk list , O. J. et al., (1975) Proc. Soc., Exp. Biol. Med. 148: (1975).116 *Pyk list , O. J. et al., J. Clin. Invest. 56:1108 (1975).117Pykalisto, O. J. et al., (1975) Proc. Soc., Exp. Biol. Med. 148: (1975).118Pykalisto, O. J. et al., J. Clin. Invest. 56:1108 (1975).119 *Rosenthal, C. J. et al., J. Clin. Invest. 55:746 (1975).120 *Rouzer, C. A. et al., Mol. Biochem. Parasitol. 2, 31 38, (1980).121Rouzer, C. A. et al., Mol. Biochem. Parasitol. 2, 31-38, (1980).122 *Rubin, C. S. et al., J. Biol. Chem. 253, 7570 7578 (1978).123Rubin, C. S. et al., J. Biol. Chem. 253, 7570-7578 (1978).124 *Sakaguchi, O., and Sakaguchi, S., Microbiol. Immunol. 23:71 85 (1979).125Sakaguchi, O., and Sakaguchi, S., Microbiol. Immunol. 23:71-85 (1979).126 *Selvan, R. et al., Indian J. Biochem. Biophys. (IJBBB), 15 (2) pp. 115 121 (1978).127Selvan, R. et al., Indian J. Biochem. Biophys. (IJBBB), 15 (2) pp. 115-121 (1978).128 *Sethi, K. K. et al., Arch. Virol. (ARVID), 59 (3) pp. 157 172 (1979).129Sethi, K. K. et al., Arch. Virol. (ARVID), 59 (3) pp. 157-172 (1979).130 *Shaw, G. M. et al., Cell Immunol. (CLIMB), 41 (1) pp. 122 133 (1978).131Shaw, G. M. et al., Cell Immunol. (CLIMB), 41 (1) pp. 122-133 (1978).132 *Sipe, J. D. et al., J. Exp. Med. 150, 597 606 (1979).133Sipe, J. D. et al., J. Exp. Med. 150, 597-606 (1979).134 *Skarnes, R. C. et al., J. Exp. Med. (JEMEA) 154 (4) pp. 1212 1228 (1981).135Skarnes, R. C. et al., J. Exp. Med. (JEMEA) 154 (4) pp. 1212-1228 (1981).136 *Spooner, P. M. et al., J. Biol. Chem. 254, 10021 10029, (1979).137Spooner, P. M. et al., J. Biol. Chem. 254, 10021-10029, (1979).138 *Spooner, P. M. et al., J. Biol. Chem. 254, 1305 1311 (1979).139Spooner, P. M. et al., J. Biol. Chem. 254, 1305-1311 (1979).140 *Student, A. K. et al., J. Biol. Chem. 255, 4745 4750, (1980).141Student, A. K. et al., J. Biol. Chem. 255, 4745-4750, (1980).142 *Sultzer, B. M. Nature (London) 219:1253 (1968).143 *Taskinen, M. et al., Diabetologia 17:351 (1979).144 *Wannemacher, R. W., Jr., et al., Infect. Immun. (INFIB) 11 (4) pp. 873 875 (1975).145Wannemacher, R. W., Jr., et al., Infect. Immun. (INFIB) 11 (4) pp. 873-875 (1975).146 *Wardley, R. C. et al., Res. J. Reticuloendothel. Soc. (RESJA), 19 (5) pp. 323 332 (1976).147Wardley, R. C. et al., Res. J. Reticuloendothel. Soc. (RESJA), 19 (5) pp. 323-332 (1976).148 *Wecker, E., et al., Ann. N.Y. Acad. Sci. (ANYAA) 249 pp. 258 263 (1975).149Wecker, E., et al., Ann. N.Y. Acad. Sci. (ANYAA) 249 pp. 258-263 (1975).150 *Werner, M., Clin. Chem. Acta. 25:299 (1969).151 *Westphal, O. et al., in Method in Carbohydrate Chemistry, eds. Whistler, R. L. BeMiller, J. N. & Wolfrom, M. L., Academic, New York) vol. 5, pp. 83 91, (1965).152Westphal, O. et al., in Method in Carbohydrate Chemistry, eds. Whistler, R. L. BeMiller, J. N. & Wolfrom, M. L., Academic, New York) vol. 5, pp. 83-91, (1965).153 *Wise, L. S. et al., Cell 13, 233 242, (1978).154Wise, L. S. et al., Cell 13, 233-242, (1978).155 *Yang, R. D. et al., 65th. Annular Meeting of the Federation of American Society for Experimental Biology, Atlanta, Ga., U.S.A., Apr. 12 17, 1981, Fed. Proc. (FEPRA), 40 (3 Part 2), p. 901 (1981).156Yang, R. D. et al., 65th. Annular Meeting of the Federation of American Society for Experimental Biology, Atlanta, Ga., U.S.A., Apr. 12-17, 1981, Fed. Proc. (FEPRA), 40 (3 Part 2), p. 901 (1981).157 *Zubler, R. H. et al., Fed. Proc. (FEPRA), 38 (3 Part 1), 1276.* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS5364793 *Dec 1, 1992Nov 15, 1994Monoclonetics International, Inc.Methods for the diagnosis of peripheral nerve damageUS5583201 *May 16, 1994Dec 10, 1996Monoclonetics International, Inc.Methods for diagnosis of peripheral nerve damageUS5656272 *Feb 4, 1994Aug 12, 1997New York University Medical CenterMethods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodiesUS5674841 *Apr 21, 1994Oct 7, 1997Genetics Institute, Inc.Method for inhibiting growth of stem cellsUS5698195 *Oct 18, 1994Dec 16, 1997New York University Medical CenterMethods of treating rheumatoid arthritis using chimeric anti-TNF antibodiesUS5733742 *Jun 3, 1994Mar 31, 1998Therapeutic Antibodies Inc.Production of antibody fragments from whole bloodUS5844097 *Jun 7, 1995Dec 1, 1998Monoclonetics International, Inc.Methods for the diagnosis of peripheral nerve damageUS5919452 *Feb 4, 1994Jul 6, 1999New York UniversityMethods of treating TNFα-mediated disease using chimeric anti-TNF antibodiesUS6011066 *Feb 2, 1998Jan 4, 2000Veterans General Hospital-TaipeiMethod for treating septic shockUS6193969Jun 3, 1994Feb 27, 2001Protherics Inc.Antibody fragments in therapyUS6277969Aug 12, 1998Aug 21, 2001New York UniversityAnti-TNF antibodies and peptides of human tumor necrosis factorUS6284471Feb 4, 1994Sep 4, 2001New York University Medical CenterAnti-TNFa antibodies and assays employing anti-TNFa antibodiesUS6790444Jan 8, 2001Sep 14, 2004New York University Medical CenterAnti-TNF antibodies and peptides of human necrosis factorUS6835823Jan 8, 2001Dec 28, 2004New York UniversityAnti-TNF antibodies and peptides of human tumor necrosis factorUS6991791Jan 18, 2001Jan 31, 2006New York University School Of MedicineAnti-TNF antibodies and peptides of human tumor necrosis factorUS7070775Jul 18, 2002Jul 4, 2006New York UniversityRecombinant A2-specific TNFα specific antibodiesUS7101674Jul 2, 2001Sep 5, 2006New York UniversityAnti-idiotypic anti-TNF antibodies and related immunoassay methodsUS7101978Jan 8, 2003Sep 5, 2006Applied Molecular EvolutionTNF-α binding moleculesUS7128907Mar 4, 2003Oct 31, 2006Centocor, Inc.Methods of treating crohn's disease with anti-TNF antibodiesUS7128908Jul 12, 2005Oct 31, 2006Centocor, Inc.Methods for treating systemic lupus erythematosus using anti-TNF antibodies and fragments thereofUS7135178Jun 20, 2002Nov 14, 2006Centocor, Inc.Methods of treating disseminated intravascular coagulation using anti-TNF antibodiesUS7135179Jul 13, 2005Nov 14, 2006Centocor, Inc.Methods for treating sarcoidosis using anti-TNF antibodies and fragments thereofUS7138118Dec 8, 2005Nov 21, 2006Centocor, Inc.Methods of treating rheumatoid arthritis with anti-TNF antibodiesUS7160542Jun 29, 2005Jan 9, 2007New York UniversityMethod of treating psoriasis using human anti-TNF antibodies and fragmentsUS7160543Dec 8, 2005Jan 9, 2007New York UniversityMethods of inhibiting TNF-α in patients with Crohn's diseaseUS7160995Jul 22, 2002Jan 9, 2007New York UniversityDNA encoding anti-TNF antibodies and peptidesUS7166284Feb 21, 2003Jan 23, 2007New York UniversityMethods of treating joint inflammation with anti-TNF antibodiesUS7169386Jan 10, 2002Jan 30, 2007New York UniversityMethods of treating inflammation associated with viral infection with anti-TNF antibodiesUS7169388Sep 30, 2004Jan 30, 2007New York UniversityMethods of inhibiting TNFα in patients with cancerUS7179466Jun 28, 2002Feb 20, 2007New York UniversityMethods of treating rheumatoid arthritis by multiple administration of anti-TNF antibodiesUS7179893Apr 7, 2006Feb 20, 2007New York UniversityRecombinant anti-TNF-α antibodiesUS7192584Aug 10, 2001Mar 20, 2007Centocor, Inc.Methods of treating psoriasis with anti-TNF antibodiesUS7204985Feb 21, 2003Apr 17, 2007Centocor, Inc.Methods of treating disseminated intravascular coagulation by multiple administration of anti-TNF antibodiesUS7214376Dec 7, 2001May 8, 2007New York UniversityMethods of inhibiting TNFα in patients with neoplastic diseaseUS7223396Dec 12, 2002May 29, 2007Centocor, Inc.Methods of treatment of fistulas in Crohn's disease with anti-TNF antibodiesUS7226593Jan 10, 2002Jun 5, 2007Centocor, Inc.Methods of treating cachexia with chimeric anti-TNF antibodiesUS7227003Jun 2, 2005Jun 5, 2007New York UniversityAnti-TNF antibody fragmentsUS7250165Aug 1, 2001Jul 31, 2007Centocor, Inc.Anti-TNF antibodies, compositions, methods and usesUS7252823Feb 6, 2004Aug 7, 2007Centocor, Inc.Recombinant A2-specific TNFα-specific antibodiesUS7276239Dec 20, 2005Oct 2, 2007Centocor, Inc.Recombinant A2-specific TNFα-specific antibodiesUS7285269Dec 2, 2003Oct 23, 2007Amgen Fremont, Inc.Antibodies directed to tumor necrosis factorUS7335358Dec 4, 2006Feb 26, 2008Centocor, Inc.Methods of treating psoriasis with anti-TNF antibodiesUS7374761Aug 8, 2007May 20, 2008Centocor, Inc.Recombinant A2-specific TNFα-specific antibodiesUS7404955Aug 2, 2005Jul 29, 2008Centocor, Inc.Methods of inhibiting or neutralizing TNFα in patients with tissue injuryUS7416729Jun 18, 2007Aug 26, 2008Centocor, Inc.Methods of treating rheumatoid arthritis with anti-TNF antibodiesUS7425330Oct 16, 2006Sep 16, 2008Centocor, Inc.Methods of inhibiting TNFα activity in the blood of a patientUS7435799Jan 8, 2004Oct 14, 2008Applied Molecular EvolutionTNF-α binding moleculesUS7517963Jan 5, 2006Apr 14, 2009Arana Therapeutics LimitedTumour necrosis factor binding ligandsUS7521206Jul 13, 2005Apr 21, 2009Centocor, Inc.Anti-TNF antibodies, compositions, methods and usesUS7528237Apr 19, 2007May 5, 2009Arana Therapeutics LimitedTumour necrosis factor binding ligandsUS7544782Feb 23, 2006Jun 9, 2009Arana Therapeutics LimitedTumour necrosis factor binding ligandsUS7553641Jun 30, 2009Arana Therapeutics LimitedTumour necrosis factor binding ligandsUS7605233Oct 20, 2009Arana Therapeutics LimitedTumour necrosis factor binding ligandsUS7691378Apr 6, 2010Centocor, Inc.Anti-TNF antibodies, compositions, methods and usesUS7744885Jun 29, 2010Centocor, Inc.Methods of treating vascular inflammatory pathology using anti-TNF antibodies and fragments thereofUS7815909Oct 19, 2010Centocor, Inc.Anti-TNF antibodies, compositions, methods and usesUS7820169Nov 11, 2008Oct 26, 2010Centocor, Inc.Anti-TNF antibodies, compositions, methods and usesUS8101178Jan 24, 2012Amgen Fremont Inc.Antibodies directed to tumor necrosis factor and uses thereofUS8241899Aug 14, 2012Centocor, Inc.Anti-TNF antibodies, compositions, methods and usesUS8415291Oct 27, 2009Apr 9, 2013Centocor Ortho Biotech Inc.Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and usesUS8603778Jul 12, 2012Dec 10, 2013Janssen Biotech, Inc.Anti-TNF antibodies, compositions, methods and usesUS8617894Mar 18, 2013Dec 31, 2013Janssen Biotech, Inc.Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and usesUS9321836Feb 18, 2014Apr 26, 2016Janssen Biotech, Inc.Anti-TNF antibodies, compositions, methods and usesUS20010027249 *Jan 8, 2001Oct 4, 2001Centocor, Inc.,Anti-TNF antibodies and peptides of human tumor necrosis factorUS20020022720 *Aug 10, 2001Feb 21, 2002New York University Medical CenterAnti-TNF antibodies and peptides of human tumor necrosis factorUS20020106372 *Jan 18, 2001Aug 8, 2002Centocor, Inc.Anti-TNF antibodies and peptides of human tumor necrosis factorUS20020114805 *Dec 7, 2001Aug 22, 2002New York University Medical CenterMethods of treating myelodysplastic syndrome with anti-TNF antibodiesUS20020141996 *Jan 10, 2002Oct 3, 2002New York University Medical Center and Centocor, Inc.Methods of treating infections with chimeric anti-TNF antibodiesUS20020146419 *Jan 10, 2002Oct 10, 2002New York University Medical CenterMethods of treating ankylosis with chimeric anti-TNF antibodiesUS20030049725 *Aug 1, 2001Mar 13, 2003George HeavnerAnti-TNF antibodies, compositions, methods and usesUS20030054004 *Jan 10, 2002Mar 20, 2003New York University Medical CenterMethods of treating cachexia with chimeric anti-TNF antibodiesUS20030079600 *Oct 4, 2002May 1, 2003Agm - Academia De Ginastica Movel Ltda.Arrangement of a rythmic apparatus with a vehicle sound apparatus, rhythmic accompaniment method and electronic transducerUS20030133935 *Jul 29, 2002Jul 17, 2003New York UniversityMethods of treating lung pathologies with chimeric anti-TNF antibodiesUS20030135029 *Dec 16, 2002Jul 17, 2003Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20030139577 *Oct 3, 2002Jul 24, 2003Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20030144484 *Jul 18, 2002Jul 31, 2003New York UniversityHuman anti-TNF antibodies and peptidesUS20030147891 *Aug 23, 2002Aug 7, 2003Centocor, Inc.Anti-TNF antibodies and peptides of human tumor necrosis factorUS20030162948 *Oct 3, 2002Aug 28, 2003Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20030166874 *Jan 14, 2003Sep 4, 2003Rathjen Deborah AnnTumour necrosis factor peptide binding antibodiesUS20030170204 *Dec 20, 2002Sep 11, 2003Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20030171553 *Jan 14, 2003Sep 11, 2003Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20030171554 *Jan 15, 2003Sep 11, 2003Rathjen Deborah AnnTumour necrosis factor peptide binding antibodiesUS20030171555 *Jan 15, 2003Sep 11, 2003Rathjen Deborah A.Tumour necrosis factor peptide binding antibodiesUS20030175275 *Jun 28, 2002Sep 18, 2003New York UniversityMethods of treatment by multiple administration of chimeric anti-TNF antibodiesUS20030175837 *Jul 2, 2001Sep 18, 2003New York University Medical CenterAnti-TNF antibodies and peptides of human tumor necrosis factorUS20030176676 *Jun 20, 2002Sep 18, 2003New York UniversityMethods of treating vascular inflammatory pathologies using chimeric anti-TNF antibodiesUS20030180299 *Jun 28, 2002Sep 25, 2003New York UniversityTreatment of heart pathology with chimeric anti-TNF antibodiesUS20030181695 *Feb 21, 2003Sep 25, 2003New York UniversityMethods of treating vascular inflammatory pathology by multiple administration of chimeric anti-TNF antibodiesUS20030187231 *Jul 22, 2002Oct 2, 2003New York UniversityHumanized anti-TNF antibodies and peptidesUS20030194402 *Dec 12, 2002Oct 16, 2003New York UniversityMethods of sustained treatment of fistulas in crohn's disease with chimeric anti-TNF antibodiesUS20030198634 *Feb 21, 2003Oct 23, 2003New York UniversityMethods of treating joint inflammation with chimeric anti-TNF antibodiesUS20030199678 *Dec 16, 2002Oct 23, 2003Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20030204066 *Feb 21, 2003Oct 30, 2003New York UniversityMethods of treating psoriatic arthritis with chimeric anti-TNF antibodiesUS20030208047 *Jan 14, 2003Nov 6, 2003Rathjen Deborah AnnTumour necrosis factor peptide binding antibodiesUS20030208049 *Dec 20, 2002Nov 6, 2003Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20030216552 *Jan 14, 2003Nov 20, 2003Rathjen Deborah AnnTumour necrosis factor peptide binding antibodiesUS20030225254 *Feb 7, 2003Dec 4, 2003Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20030232970 *Dec 16, 2002Dec 18, 2003Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20030232971 *Jun 2, 2003Dec 18, 2003Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20040002588 *Dec 20, 2002Jan 1, 2004Rathjen Deborah AnnTumour necrosis factor binding ligandsUS20040002589 *Jan 14, 2003Jan 1, 2004Rathjen Deborah AnnTumour necrosis factor peptide binding antibodiesUS20040002590 *Jan 15, 2003Jan 1, 2004Rathjen Deborah AnnTumour necrosis factor peptide binding antibodiesUS20040092721 *Jan 15, 2003May 13, 2004Rathjen Deborah AnnTumour necrosis factor peptide binding antibodiesUS20040120952 *Aug 8, 2003Jun 24, 2004Centocor, IncAnti-TNF antibodies and peptides of human tumor necrosis factorUS20040131612 *Jan 8, 2003Jul 8, 2004Watkins Jeffry D.TNF-alpha binding moleculesUS20040138427 *Feb 6, 2004Jul 15, 2004Centocor, Inc.Anti-TNF antibodies and peptides of human tumor necrosis factorUS20040214993 *Oct 3, 2002Oct 28, 2004Deborah RathjenTumour necrosis factor binding ligandsUS20050037008 *Sep 30, 2004Feb 17, 2005Centocor, Inc.Methods of treating carcinoma using anti-TNF antibodies and fragments thereofUS20050049402 *Dec 2, 2003Mar 3, 2005Babcook John S.Antibodies directed to tumor necrosis factor and uses thereofUS20050074454 *Sep 30, 2004Apr 7, 2005Centocor, Inc.Methods of treating carcinoma using anti-TNF antibodies and peptidesUS20050249735 *Dec 13, 2004Nov 10, 2005Centocor, Inc.Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factorUS20050255104 *Feb 7, 2005Nov 17, 2005Centocor, Inc.Methods of treating psoriasis using anti-TNF receptor fusion proteinsUS20050260201 *Feb 7, 2005Nov 24, 2005Centocor, Inc.Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteinsUS20060013816 *Jun 29, 2005Jan 19, 2006Centocor, Inc.Method of treating psoriasis using human anti-TNF antibodies and fragmentsUS20060018907 *Jul 14, 2005Jan 26, 2006Centocor, Inc.Anti-TNF antibodies and peptides of human tumor necrosis factorUS20060121037 *Dec 8, 2005Jun 8, 2006Junming LeAnti-TNF antibodies and peptides of human tumor necrosis factorUS20060140949 *Dec 20, 2005Jun 29, 2006Junming LeHuman anti-TNF antibodies and peptidesUS20060140951 *Feb 22, 2006Jun 29, 2006Rathjen Deborah ATumour necrosis factor binding ligandsUS20060159677 *Mar 7, 2006Jul 20, 2006Peptech LimitedTumour necrosis factor peptide binding antibodiesUS20060182746 *Jan 5, 2006Aug 17, 2006Rathjen Deborah ATumour necrosis factor binding ligandsUS20060204499 *May 8, 2006Sep 14, 2006Peptech LimitedTumour necrosis factor binding ligandsUS20060222646 *Mar 2, 2006Oct 5, 2006George TreacyAnti-TNFalpha antibodies in therapy of asthmaUS20060233802 *Jun 6, 2006Oct 19, 2006Peptech LimitedTumour necrosis factor binding ligandsUS20060240017 *Apr 7, 2006Oct 26, 2006Junming LeHuman anti-TNF antibodies and peptidesUS20060269549 *Jan 8, 2004Nov 30, 2006Watkins Jeffry DTnf-alpha binding moleculesUS20060280742 *Dec 8, 2005Dec 14, 2006Junming LeMethods of inhibiting tnf-alpha in patients with crohn's diseaseUS20070009524 *Jan 10, 2002Jan 11, 2007New York University Medical CenterMethods of treating inflammation associated with viral infection with anti-tnf antibodiesUS20070077248 *Feb 23, 2006Apr 5, 2007Peptech LimitedTumour necrosis factor binding ligandsUS20070141057 *Dec 4, 2006Jun 21, 2007Junming LeAnti-TNF antibodies and peptides of human tumor necrosis factorUS20070287177 *Jun 7, 2007Dec 13, 2007Rathjen Deborah ATumour necrosis factor binding ligandsUS20080003228 *Jun 18, 2007Jan 3, 2008Junming LeMethods of treating rheumatoid arthritis with anti-tnf antibodiesUS20080187531 *Oct 22, 2007Aug 7, 2008Babcook John SAntibodies directed to tumor necrosis factor and uses thereofUS20090022718 *Dec 7, 2007Jan 22, 2009Centocor, Inc.Methods of treating a blood pathology using anti-TNF antibodies and fragments thereofUS20090038182 *Aug 9, 2007Feb 12, 2009Lans Maris JFootwear with built-in scaleUS20090081234 *Nov 20, 2008Mar 26, 2009George HeavnerAnti-tnf antibodies, compositions, methods and uses for treatment of depression and related conditionsUS20090081241 *Nov 14, 2008Mar 26, 2009George HeavnerAnti-TNF Antibodies, Compositions, Methods and UsesUS20090252743 *Nov 11, 2008Oct 8, 2009George HeavnerAnti-TNF Antibodies, Compositions, Methods and UsesUS20100144601 *Oct 27, 2009Jun 10, 2010Steven JacobsAnti-TNF Alpha Fibronectin Type III Domain Based Scaffold Compositions, Methods and UsesUS20110195063 *Sep 17, 2010Aug 11, 2011Centocor, Inc.Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor* Cited by examinerClassifications U.S. Classification514/4.8, 530/389.1, 530/838, 530/395, 514/909, 530/417, 530/350, 530/829, 424/158.1, 514/7.4, 514/21.92International ClassificationC07K14/47, C12P1/00, C07K16/24, A61K39/00, A61K38/00, G01N33/53, C07K16/38, C07K14/52, C12N5/0789Cooperative ClassificationY10S514/909, Y10S530/829, Y10S530/838, G01N2400/40, A61K39/00, G01N33/53, C12N2501/22, C12P1/00, C07K16/24, G01N2333/52, C12N5/0647, C07K14/4703, C07K16/38, C07K14/523, C12N2501/21, A61K38/00, C07K16/241European ClassificationC12P1/00, C07K14/52A2, C07K16/24, C12N5/06B11P, C07K16/24B, C07K14/47A1A, G01N33/53, C07K16/38Legal EventsDateCodeEventDescriptionAug 13, 1992FPAYFee paymentYear of fee payment: 4Sep 23, 1996FPAYFee paymentYear of fee payment: 8Nov 7, 2000REMIMaintenance fee reminder mailedApr 15, 2001LAPSLapse for failure to pay maintenance feesJun 19, 2001FPExpired due to failure to pay maintenance feeEffective date: 20010418RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services